Tandem Diabetes (TNDM) Q4 2025 earnings review
Record Margins and a Strategic Pivot to Recurring Revenue
Tandem closed FY25 with a strong beat, delivering record Q4 sales of $290M (+15% YoY adjusted) and hitting a historic 58% gross margin. The company is now aggressively transitioning its business model: shifting U.S. sales to a 'pay-as-you-go' pharmacy model and taking European operations direct. While this creates a reported revenue headwind of ~$90M for FY26, it accelerates profitability. FY26 guidance forecasts positive Adjusted EBITDA margins of 5-6% (up from -5% in FY25), signaling that the long-promised operational leverage is finally materializing.
🐂 Bull Case
Gross margin expanded to 58% in Q4 (up from 51% a year ago), driven by the shift to pharmacy channels and manufacturing efficiencies. FY26 guidance maintains this high level (56-57%), proving the profitability model works.
Despite accounting headwinds from the business model shift, U.S. pump shipments are guided to grow 10-11% in FY26. Demand remains robust, fueled by the Mobi platform.
🐻 Bear Case
Cash and equivalents dropped to $292M from $438M a year ago. While Q4 Free Cash Flow was positive ($3.1M), the buffer is shrinking as they fund major commercial transitions in Europe.
FY26 revenue guidance of $1.065-$1.085B includes a massive ~$90M headwind from the accounting shift (pay-as-you-go + direct operations). This creates 'optical' slow growth that may spook generalist investors.
⚖️ Verdict: 🟢
Bullish. The strategic pivot is messy on paper but healthy for the business. Hitting 11% EBITDA margin in Q4 and guiding for full-year profitability in FY26 validates the turnaround thesis. The underlying double-digit volume growth is the real signal.
Key Themes
The Pharmacy Channel 'Pay-As-You-Go' Shift
Tandem is moving U.S. customers to a 'pay-as-you-go' pharmacy model rather than the traditional upfront Durable Medical Equipment (DME) purchase. While this creates a $70-$80M revenue headwind in FY26 (revenue is recognized over time rather than upfront), it reduces patient out-of-pocket costs and builds a highly predictable recurring revenue stream.
Gross Margin Expansion
Accelerating. Gross margin hit a record 58% in Q4, significantly above the 51% seen in Q4 2024. This was driven by the pharmacy channel mix (higher ASPs) and Mobi manufacturing efficiencies. Management guided FY26 GM to 56-57%, confirming this is a structural improvement, not a one-off.
International Transition Risk
Tandem is terminating distributor relationships to go direct in select European countries. This creates a $15M sales headwind in FY26 and operational execution risk. While direct operations yield higher margins long-term, the transition period often involves inventory destocking and logistical friction.
GAAP Profitability Still Elusive
Despite the 'Adjusted' EBITDA success, the company posted a GAAP Net Loss of $204M for FY25 and $0.6M for Q4. Stock-based compensation ($92M in FY25) remains a significant expense that adjusts profitability metrics upwards significantly.
Mobi Platform Traction
The Mobi pump is driving volume. Worldwide pump shipments reached 38,000 in Q4, with U.S. shipments at 27,000. Management cited 'record quarterly sales' and noted the launch of Android control for Mobi, removing a key barrier to adoption.
Other KPIs
Accelerating. Reported +3% GAAP growth, but +15% on a Non-GAAP basis (excluding prior year Tandem Choice deferrals). Beat the implied run-rate from Q3 ($249M).
Stable/Accelerating. Up from ~20k in Q3 2025 and 24k in Q4 2024. Indicates strong demand for the Mobi platform despite competitive pressures.
Reversing. Turned positive in the quarter, contributing to positive Free Cash Flow of $3.1M. Critical pivot as cash balance ($292M) had been declining throughout the year.
Guidance
Stable. Implies ~6% reported growth over FY25 ($1.015B). However, underlying volume growth is double-digit, masked by ~$90M in business model transition headwinds.
Accelerating. A massive swing from -5% in FY25. Management is effectively guiding for ~$50-60M in positive EBITDA, driven by the gross margin expansion to 56-57%.
Accelerating. Strong volume guidance suggests the 'pay-as-you-go' model is lowering barriers to entry for patients, validating the strategy.
Stable. Includes $80M in stock-based compensation. While lower than FY25 ($92M), it remains a high percentage of revenue (~9%).
Key Questions
Cash Flow Dynamics of Pay-As-You-Go
How does the shift to pay-as-you-go impact working capital and cash conversion cycles in H1 2026? Will we see a cash trough before recurring revenue builds up?
European Direct Costs
What are the upfront OPEX investments required for the European direct transition, and are these fully baked into the 5-6% EBITDA guidance?
Mobi vs. t:slim Mix
With the Android launch for Mobi, are you seeing cannibalization of t:slim X2, or is Mobi primarily driving new MDI (Multiple Daily Injection) conversions?